The primary catalyst is PALISADE-4 topline results expected within days. Positive results could drive a significant rally given the $23M market cap and prior PALISADE-2 success; negative results would likely lead to substantial downside given limited pipeline and cash runway. Monitor for the press release and consider positioning ahead of the binary event.
Price Chart
Executive Summary
Vistagen reported fiscal year 2026 financial results with net loss widening to $69.7M and cash at $45.4M, while providing pipeline updates including the imminent PALISADE-4 Phase 3 topline readout for fasedienol in social anxiety disorder. The filing is a routine pre-revenue biotech earnings update with no financial surprises; the stock will move on the binary PALISADE-4 results expected this month.
Key Facts
- Total revenues for FY2026 were $1.269M (sublicense and other), up from $0.486M in FY2025.
- Net loss was $69.685M for FY2026, compared to $51.418M in FY2025.
- Cash, cash equivalents, and marketable securities were $45.4M as of March 31, 2026, sufficient to fund operations into 2027.
- PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder: randomized portion completed, topline results expected in June 2026.
- Phase 2 repeat dose study of fasedienol completed randomized portion, topline results expected in Q3 2026.
- FDA issued 'Study May Proceed' letter for refisolone IND for vasomotor symptoms due to menopause.
- Minimum ICH E1 safety exposure achieved with >1,500 individuals exposed to fasedienol.
Financial Impact
Net loss increased 35.5% YoY to $69.7M; cash burn rate approximately $24M/year. The upcoming PALISADE-4 readout is a binary catalyst that could swing market cap by >50%.
Risk Factors
- PALISADE-4 may fail to meet its primary endpoint, similar to PALISADE-3, which would severely impair the pipeline.
- Cash runway only into 2027; failure of PALISADE-4 could necessitate dilutive financing or restructuring.
- No approved products or recurring revenue; stock is entirely dependent on clinical trial outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-043232 |
| Document: vtgn-20260615.htm | 0001628280-26-043232 |
| Document: 0001628280-26-043232-index-headers.html | 0001628280-26-043232 |
| Document: 0001628280-26-043232-index.html | 0001628280-26-043232 |
| Document: 0001628280-26-043232.txt | 0001628280-26-043232 |
| 8-K Data (Synthetic) | 0001628280-26-043232 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.2676 $0.2432 | ▲ +9.12% | ▲ +7.13% | $0.2847 (−6.39%) |
Aug 14, 2026 7w ago | Press Release | $0.2676 $0.2432 | ▼ −9.12% | ▼ −7.13% | $0.2847 (+6.39%) |
Jul 31, 2026 9w ago | 8-K | $0.2410 $0.2529 | ▲ +4.94% | ▲ +1.95% | $0.2847 (+18.13%) |
Jun 30, 2026 13w ago | 8-K | $0.2260 $0.2302 | ▼ −1.86% | ▼ −2.89% | $0.2847 (−25.97%) |
Jun 17, 2026 15w ago | 8-K | $0.6702 $0.2400 | ▼ −64.19% | ▼ −64.72% | $0.2847 (−57.52%) |
Jun 15, 2026 15w ago | 8-K | $0.6900 $0.2461 | ▼ −64.33% | ▼ −64.53% | $0.2847 (−58.74%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.5731 $0.2492 | ▼ −56.52% | ▼ −58.41% | $0.2847 (−50.32%) |
Jun 9, 2026 16w ago | 8-K | $0.5351 $0.2492 | ▼ −53.43% | ▼ −57.05% | $0.2847 (−46.79%) |
May 19, 2026 19w ago | 8-K | $0.6400 $0.6702 | ▲ +4.72% | ▲ +3.98% | $0.2847 (−55.52%) |
May 12, 2026 20w ago | 8-K | $0.6200 $0.5400 | ▼ −12.90% | ▼ −11.18% | $0.2847 (−54.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access